Rheumatoid arthritis (RA) is the largest indication — it affects 1.3 million Americans, and TNF inhibitors are first‑line after methotrexate. Psoriasis is the fastest‑growing indication, driven by the approval of TNF inhibitors for psoriatic arthritis and plaque psoriasis. The TNF alpha inhibitors market research shows that psoriasis will grow at over 4% CAGR, faster than RA.

What's the difference? In RA, TNF inhibitors are used with methotrexate. In psoriasis, they're often used alone or with topical therapy. The TNF alpha inhibitors market trends highlight that the fastest‑growing route of administration is subcutaneous, because patients can self‑inject at home.

But TNF inhibitors have side effects: increased risk of infections (TB, fungal), and rare cases of lymphoma or demyelinating disease. That's why patients are screened before starting.

The bottom line: if you have moderate‑to‑severe RA or psoriasis, TNF inhibitors are highly effective. But they're not for everyone. Discuss risks and benefits with your rheumatologist.